🟢 NeOnc Technologies Holdings is trading 14.58% up in pre-market ahead of August 12 NEO100 readout

NeOnc Technologies Holdings is trading 14.58% up at $4.98 now as investors position ahead of the August 12, 2026 topline Phase 2a readout for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma.

• The fully enrolled study’s efficacy, safety, and regulatory updates are scheduled for an 8:30 a.m. ET investor call.
• The August 10 earnings release confirmed the imminent catalyst while reporting a wider second-quarter loss.